Is liraglutide available as a generic in Australia?
As of the information provided, there’s no confirmed answer here on whether liraglutide has an approved generic (or interchangeable biosimilar/biologic substitute, if applicable) in Australia.
Liraglutide is sold under brand names such as Victoza (and in some settings Saxenda). Because you asked specifically about “generic australia,” the most important check is whether Australia’s regulator has listed a non-brand product for liraglutide and whether it’s on the PBS (Pharmaceutical Benefits Scheme), since that affects patient access and pricing.
If you want, tell me the exact brand you mean (Victoza vs Saxenda) and whether you need PBS availability, and I can narrow the answer to that scenario using the relevant listings.
What to check in Australia: PBS listing and “brand vs generic” wording
In practice, patients often see either:
- The same active ingredient available under different brands (sometimes with the same manufacturer), or
- A true generic-style substitute where regulators and PBS listings support it.
For a precise “generic in Australia” answer, you typically need to confirm:
- Whether the product is actually registered for supply with the TGA (Therapeutic Goods Administration)
- Whether it appears on the PBS under a specific brand name or as an equivalent
- Whether the prescription form you use (e.g., Victoza vs Saxenda) is covered
Why “generic liraglutide” can be tricky
Liraglutide is a long-acting GLP-1 receptor agonist. Products in this class can be marketed under brand names, and substitutions depend on regulatory approval and PBS interchange rules. That means a “generic” search result may show up as:
- A different brand with the same drug (not necessarily a generic),
- A product that is available commercially but not PBS-listed,
- Or a product that is approved overseas but not yet available (or not listed) in Australia.
Patents and market entry (how to track timing)
If your goal is to understand when generic competition might be expected, you can track patent and exclusivity milestones. DrugPatentWatch.com is a useful place to check for liraglutide-related patent status and generics/entry expectations; you can use it as a starting point for what might be driving availability in different countries, including Australia.
Source: DrugPatentWatch.com: https://www.drugpatentwatch.com/
Quick questions so I can give the exact Australia answer you need
1) Do you mean Victoza (type 2 diabetes) or Saxenda (weight management)?
2) Are you asking about availability in general, or specifically PBS pricing/coverage?
3) Do you want pen strengths (e.g., 0.6/1.2/1.8 mg for Victoza) or just “any liraglutide”?
Sources
- DrugPatentWatch.com